ZNTL Zentalis Pharmaceuticals
- 12.338
- +0.028+0.22%
Zentalis Pharmaceuticals News
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
Zentalis Pharmaceuticals (ZNTL) has an average outperform rating and a price target range of $15 to $50, according to analysts polled by Capital IQ. Price: 12.06, Change: -0.25, Percent Change: -2.03
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
Stifel Maintains Buy on Zentalis Pharma, Lowers Price Target to $32
Stifel analyst Bradley Canino maintains Zentalis Pharma with a Buy and lowers the price target from $36 to $32.
Zentalis Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 159.95% Stifel $36 → $32 Maintains Buy 02/28/2024 273.68% HC Wainwright & Co. → $46 Reiterates
Buy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of Azenosertib
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts With Strategic ...
Zentalis Pharma's Q1 Cash, Cash Equivalents and Marketable Securities Position Of $489M Is Expected To Provide Cash Runway Into Mid-2026
Zentalis Pharma's Q1 Cash, Cash Equivalents and Marketable Securities Position Of $489M Is Expected To Provide Cash Runway Into Mid-2026
Zentalis Pharma Q1 2024 GAAP EPS $0.14 May Not Be Comparable To $(0.73) Estimate, Sales $40.560M May Not Be Comparable To $13.125M Estimate
Zentalis Pharma Q1 2024 GAAP EPS $0.14 May Not Be Comparable To $(0.73) Estimate, Sales $40.560M May Not Be Comparable To $13.125M Estimate
Zentalis Pharmaceuticals | 10-Q: Quarterly report
Zentalis Pharmaceuticals 1Q EPS 14c >ZNTL
Zentalis Pharmaceuticals 1Q EPS 14c >ZNTL
Press Release: Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress Azenosertib clinical development plan on track with multiple data readouts in gynecological and other ca
Zentalis Pharmaceuticals Shares Are Trading Lower After the Company Announced a CFO Transition.
Zentalis Pharmaceuticals Shares Are Trading Lower After the Company Announced a CFO Transition.
Zentalis Shares Fall After Chief Financial Officer Resigns
By Colin Kellaher Zentalis Pharmaceuticals shares moved lower Thursday after the clinical-stage biopharmaceutical company's top finance executive resigned. Shares of the New York company were recent
Zentalis Pharmaceuticals Says Melissa Epperly Resigns as CFO
Zentalis Pharmaceuticals Announces Executive Financial Transition
Zentalis Pharmaceuticals to Present at Upcoming Conferences
Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With KRAS(G12C) Inhibitors At AACR Annual Meeting 2024
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers
PLAB, SMTC and WOOF Are Among After Hour Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 73.2% to $1.1 during Thursday's after-market session. The company's market cap stands at $39.3 million. Sunshine Biopharma (NASDAQ:SBFM) sha
Analysis
Price Target
No Data
